ClinicalTrials.gg
Status unknownNCT04185753Updated Dec 4, 2019

Chronotropic Incompetence During Exercise Testing in Obese Adolescents

An observational study in Obesity, Childhood, Cardiac Disease and Cardiovascular Risk Factor, sponsored by Hasselt University. Status unknown at 1 site in Belgium. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-12-04.

Sponsored by Hasselt University · Observational

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
60
Ages
11 Years to 17 Years
Sex
All
01

Study summary

In adolescents with obesity cardiopulmonary exercise testing (CPET) has become an important clinical examination providing valuable information with regard to the integrative exercise responses, including the pulmonary, cardiovascular and muscular systems.

During CPET, mechanical constraints in ventilation, an elevated risk for hypoxia and chronotropic incompetence (CI) (defined as the inability of the heart to increase its rate with increased activity), or compromised cardiac function (e.g. lowered heart rate (HR) recovery, chronotropic index and stroke volume) are often observed in obese adults. Moreover, several studies regarding exercise capacity and cardiopulmonary responses to maximal endurance exercise testing have been performed in obese adolescents. Despite these previous investigations in obese adolescents it remains controversial whether cardiopulmonary disturbances can be observed consistently during CPET. However, a number of studies have reported a suboptimal response to exercise, in particular a reduced peak heart rate (HRpeak) and peak cycling power output (Wpeak). Adult obesity modifies cardiac behavior, including resting HR and CI, which has a marked effect on exercise capacity. Therefore, chronotropic variables are the most important factors that affect exercise performance. It has been shown that both peak and resting HR account for over forty percent of variability of exercise capacity. Interestingly, resting HR and HR response to exercise, including a blunted HR increase, low chronotropic index and HR recovery, are important predictors of all-cause mortality and cardiovascular death, at least in adults. These changes in HR during and recovery from CPET are mediated by the balance between sympathetic and vagal activity of the autonomic nervous system. Adverse cardiovascular outcomes associated with the metabolic syndrome may be mediated by autonomic dysfunction, whereby obesity is characterized by sympathetic predominance and a decrease in vagal activity in the basal state, where reduced sympathetic responsiveness has been observed during exercise. Therefore, these multiple exercise risk markers could provide valuable clinical information regarding cardiometabolic health. Nonetheless HR behavior during CPET has not been described in obese adolescents. The goal of this study is to examine the HR behavior of obese adolescents during CPET to clarify whether this population suffer from CI.

02

Conditions studied

  • Obesity, Childhood
  • Cardiac Disease
  • Cardiovascular Risk Factor
03

In context

Pediatric Obesity

1,126 studies on the registry are indexed under Pediatric Obesity; 189 are open to participants now.

This study's planned enrollment of 60 is below the median of 180 across 233 observational studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

Hasselt University is the lead sponsor of 203 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Obese adolescents

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obese or lean (based on extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity)
  • Parental permission

Exclusion criteria

Exclusion Criteria:

  • Chronic cardiovascular, renal, pulmonary or orthopaedic disease
  • Medication use that could possibly influence the heart rate
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Obese adolescents with CI

    Obese adolescents with chronotropic incompetence

    Diagnostic Test: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

  • Control group

    Obese adolescents without chronotropic incompetence

    Diagnostic Test: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

Interventions

  • Diagnostic testThe prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

    The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

06

What researchers measure

Primary outcomes

  1. Heart rate (HR) during exercise testing

    Assessed using a 12-lead ECG device

    Time frame: day 1

  2. Peak oxygen uptake (VO2) during exercise testing

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VO2 is collected breath-by-breath and averaged every ten seconds.

    Time frame: day 1

  3. Peak workload during exercise testing

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed and the incremental workload is measured

    Time frame: day 1

Secondary outcomes

  1. Body height

    Body height is measured to the nearest 0.1cm using a wall-mounted Harpenden stadiometer, with participants barefoot

    Time frame: day 1

  2. Body weight

    Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg

    Time frame: day 1

  3. Waist circumference

    Waist circumference will be measured to the nearest 0.1cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Waist circumference is measured at the midpoint between the lower rib margin and the top of the iliac crest.

    Time frame: day 1

  4. Hip circumference

    Hip circumference will be measured to the nearest 0.1cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Hip circumference is measured at the widest circumference of the hip at the level of the greater trochanter.

    Time frame: day1

  5. Physical activity questionnaire for adolescents (PAQ-A)

    physical activity determined using the validated Dutch physical activity questionnaire for adolescents

    Time frame: day 1

  6. Tanner stage

    Puberty stage (ranging from 1 to 5) will be assessed in all participants by the pediatric endocrinologist using Tanner staging criteria.

    Time frame: day 1

  7. Plasma glucose

    Blood analyses

    Time frame: day 1

  8. Total cholesterol

    Blood analyses

    Time frame: day 1

  9. High-density lipoprotein cholesterol

    Blood analyses

    Time frame: day 1

  10. Low-density lipoprotein cholesterol

    Blood analyses

    Time frame: day 1

  11. Triglyceride concentration

    Blood analyses

    Time frame: day 1

  12. C-reactive protein

    Blood analyses

    Time frame: day 1

  13. Serum leptin concentration

    Blood analyses

    Time frame: day 1

  14. Insulin

    Blood analyses

    Time frame: day 1

  15. Homeostatic model assessment for insulin resistance (HOMA-IR)

    Homeostatic model assessment for insulin resistance calculated from insulin and glucose concentration

    Time frame: day 1

  16. Carbon dioxide output (VCO2) during exercise testing

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VCO2 is collected breath-by-breath and averaged every ten seconds.

    Time frame: day 1

  17. Minute ventilation(VE) during exercise testing

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE is collected breath-by-breath and averaged every ten seconds.

    Time frame: day 1

  18. Tidal volume (Vt) during exercise testing

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis Vt is collected breath-by-breath and averaged every ten seconds.

    Time frame: day 1

  19. Breathing frequency (BF) during exercise testing

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis BF is collected breath-by-breath and averaged every ten seconds.

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
  • Virga Jesse hospital - Heart centre Hasselt
    Hasselt, Limburg 3500, Belgium
    • Dominique Hansen, prof. dr. · Contact · dominique.hansen@uhasselt.be · +32 11 29 21 26
    • Wouter Franssen, MSc · Sub investigator
    • Charly Keytsman, Dr. · Sub investigator
    • Nastasia Marinus, MSc · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04185753
Lead sponsor
Hasselt University
Responsible party
Dominique Hansen (Principal Investigator, Hasselt University) — Principal investigator
First posted
Dec 4, 2019
Start date
Nov 29, 2019 (estimated)
Primary completion
Jan 15, 2020 (estimated)
Completion
Jan 30, 2020 (estimated)
Last update
Dec 4, 2019

Study contacts

Dominique Hansen, Prof.
Contact
dominique.hansen@uhasselt.be
+32(0)11 292126
Dominique Hansen, PhD
principal investigator · Hasselt University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion